Autopsy report · NCT04047693

Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma

“Poor accrual due to increased use of alternative neoadjuvant treatment options.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 4 years 6 months before it stopped.
• 24 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Pusan National University Yangsan Hospital

Sponsor type

University, hospital or other

Conditions

Muscle Invasive Bladder Cancer; Urothelial Carcinoma; Neoadjuvant Chemotherapy

Interventions

dose dense MVAC with pegylated GCSF

Participants

24

Sites

1

Countries

South Korea

Trials that died the same way

• To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
  “Enrollment was delayed and the number of eligible patients significantly declined with the use of neoadjuvant or adjuvant ICIs and TKIs therapies. Thus, this trial was closed due to insufficient accrual.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.